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Highlights 
 Dominant CALR clone in Essential Thrombocytosis with low frequency JAK2 V617F. 
 CALR clone dictates the disease phenotype in ET with concomitant JAK2 V617F. 
 Extended molecular diagnostics is warranted in low frequency JAK2 V617F MPNs. 
Abstract 
Detection of somatic mutations in cardinal driver genes is a strong argument for diagnosis in classical Philadelphia-
negative myeloproliferative neoplasms (MPN). Driver mutations in JAK2, CALR and MPL, are generally considered 
mutually exclusive, but several reports have suggested that they co-exist in a small subgroup of patients. 
In this study we retrospectively analyzed for CALR mutations in 136 suspected MPN patients with low allelic burden 
(≤5%) JAK2 V617F. Fifteen patients with concomitant JAK2 V617F and CALR mutation were identified of which ten were 
diagnosed with essential thrombocytosis (ET). More than 50 different indel mutations in exon 9 of CALR have been 
reported, with type 1 (52 bp deletion) and type 2 (5 bp insertion) accounting for more than 80% of CALR mutated MPN 
cases. Type 1 is generally considered the most common mutation, but interestingly, our double mutated ET patients 
seem to have an inversed ratio between type 1 and type 2 CALR mutations. 
Our findings support the possibility of co-existing JAK2 V617F and CALR mutations and stress the importance of further 
molecular screening in MPN patients with low allele frequencies of JAK2 V617F.  
Keywords 
Essential thrombocytosis; CALR; JAK2 V617F; myeloproliferative neoplasms; driver mutations 
Introduction 
The classical Philadelphia-negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential 
thrombocytosis (ET) and primary myelofibrosis (PMF), are a group of clonal hematopoietic stem cell disorders 
characterized by the overproduction of terminally differentiated and fully functional hematopoietic cells. Major 
molecular diagnostic criteria for the MPNs, include presence of somatic mutations in cardinal driver genes; JAK2 V617F 
or JAK2 exon 12 in PV and JAK2 V617F, CALR exon 9 or MPL exon 10 in ET and PMF[1].  
The MPN driver mutations are generally considered mutually exclusive and with detection of the common JAK2 V617F 
mutation usually no further testing is performed. However, in recent years papers have been published suggesting that 
driver mutations indeed do co-exist[2-4].  
Detection of such 'double mutant' patients could very well have clinical implications. There is a general consensus that 
the mutation type affects the phenotypic manifestations and prognosis. Patients with JAK2 mutation often exhibit more 
prominent leukocytosis, lower levels of platelets, higher hemoglobin levels, more thrombotic events and chance of 
transformation into AML. CALR mutations are characterized by lower risk of thrombosis, lower hemoglobin and 
leukocyte counts, higher platelets levels and a better overall survival [5, 6].  We wanted to address the issue of double 
mutants in our patients to ensure adequate molecular characterization for aiding clinicians providing more precise 
diagnoses and prognostication in patients with PMF and ET. 
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Methods 
In this study, we retrospectively reanalysed for CALR mutation in all suspected MPN patients initially analysed for JAK2 
V617F between January 2012 and April 30
th
 2015 for whom allele frequencies of the JAK2 mutation was between 0.01% 
and 5%. 136 patients were positive for JAK2 V617F with allele frequencies in this range. In addition, a smaller test group 
of 46 patients with JAK2 V617F allele frequencies between 6% and 10% were analysed. The JAK2 V617F analysis was 
performed with allele specific qPCR with sensitivity at 0.01% as described previously [7]. CALR exon 9 mutations were 
analysed by fragment length analysis with sensitivity at 2% as described previously [8].
 
All samples positive for a CALR 
mutation were confirmed by Sanger sequencing to determine the specific type of CALR exon 9 mutation. Statistical 
analyses were performed by Fisher's Exact Test and Student's T-test. The study was approved by the local ethical 
committee and the Danish Data Protection Agency.  
Results and discussion 
We identified 15 patients with concomitant CALR mutation within the group of 136 patients with JAK2 V617F allele 
frequencies (VAF) ≤5% while none of the 46 patients with JAK2 V617F VAF >5% had a CALR mutation (p=0.013). Clinical 
data, collected at diagnosis prior to any treatment, and mutational status of the 15 double mutated patients can be seen 
in Table 1. The identification of concurrent CALR mutation within the group of suspected MPN patients with low JAK2 
V617F allele frequencies is in line with previous studies. Mansier et al reported concurrent CALR mutation in only 2 of 
412 patients (0.5%) with JAK2 V617F VAF >5% while in 19 of 133 patients (14%) with JAK2 V617F VAF <5% and Usseglio et 
al observed concurrent JAK2 V617F and CALR/MPL mutation exclusively in patients with JAK2 V617F VAF<5% [2, 3]. 
Ten of our double mutated patients were diagnosed with ET, three with PMF and two patients were MPN-unclassifiable.  
JAK2 V617F and CALR double mutation have been previously observed in both ET and PMF but with at preponderance 
for ET as also observed in the current study [3, 9, 10]. 
More than 50 different indel mutations in exon 9 of CALR have been found with type 1 (52 bp deletion) and type 2 (5 bp 
insertion) as the most common variants. In our double mutated patients we identified five type 1 (33%) and ten type 2 
(66%) CALR mutations and in the ET group 3 patients were found positive for CALR mutation type 1 (30%) and seven 
were positive for type 2 (70%). More type 1 (53%) than type 2 (32%) CALR mutations are found in MPN patients in 
general [8] while the rest are classified as either type 1-like, type2-like or 'other types', based on the remaining stretches 
of negatively charged amino acids in the mutant proteins [11]. The distribution of CALR mutations is hence 57% type 1-
like and 39% type 2-like in ET, and 83% type 1-like and 15% type 2-like in PMF [11]. The clinical significance of type 1 
versus type 2 CALR mutations is, however, debated. A recent report indicate that type 1 mutations are associated with 
PMF or ET with an increased risk of myelofibrotic transformation, while type 2 mutations are associated with ET, low risk 
of thrombosis and indolent clinical course[11]. Another report on ET patients showed that patients with type 2 variants 
displayed significantly higher platelet count but that the two CALR mutation variants were similar in their hemoglobin 
level, leukocyte count, IPSET (International Prognostic Scoring System for Essential Thrombocythemia) scores and in 
overall and thrombosis-free survival [12]. A third report suggests that the prognostic advantage of CALR mutations in 
PMF might be confined to type 1 or type 1-like CALR variants [13].  
The skewed frequencies of type 1 versus type 2 mutations observed in the present study could, however, indicate that 
double mutated patients constitute a distinct MPN entity. This hypothesis is supported by a recent report that found an 
association between concurrent JAK2 V617F and CALR/MPL mutation and higher age compared to single mutated ET 
patients [9]. However, this could not be confirmed in our cohort where the  mean age of our double mutated ET patients 
was 64.1 years while 59.3 years in 66 ET patients diagnosed at our institution with CALR mutation alone (p=0.31). 
Our double mutated ET patients had median thrombocyte count at 1195 x10
6
/l. Erythrocyte volume fraction was within 
normal range for all ET patients (not shown), one patient had slightly lowered hemoglobin level, and all except one 
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patient had moderate increased lactate dehydrogenase (Table 1). Two of 3 ET patients with type 1 mutation experienced 
deep venous thrombosis (DVT) or Non ST-Elevation Myocardial Infarction (non-STEMI) two years prior to diagnosis while 
only one patient out of seven with type 2 mutation had DVT two years post diagnosis. Even though this is a small study, 
these results could imply that type 1 CALR mutations are more frequently associated with thrombosis than type 2 CALR 
mutations as also suggested previously [11]. None of the ET patients progressed to myelofibrosis during a median follow-
up time at 59 months and all ET patients were alive at end of follow-up. 
We searched for CALR mutations in 136 patients with low allele burden JAK2 V617F (≤5%) and identified CALR mutations 
with allele frequencies in the range 9 - 44% in 15 (11%) of these patients, stressing that the CALR clone is the dominant 
one in our double mutated cases in accordance with previous studies [2, 3]. This finding, in combination with the high 
thrombocyte count and few thrombotic events in ET patients with type 2 mutation, indicate that the CALR clone and 
mutation subtype dictate the disease phenotype in double mutant patients. Future studies are warranted for clarifying 
the etiology of double mutated MPN patients and whether mutations arise in the same or two different tumor clones. 
In conclusion, our data stress the importance of extending the molecular screening in suspected MPN patients with low 
allele frequencies of JAK2 V617F (e.g ≤3%) to also include CALR in order to confirm the MPN diagnosis and refine 
prognostication.  
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Table 1. Clinical and mutational characteristics of the fifteen patients with concomitant JAK2 V617F and CALR 
mutation. VAF: variant allele frequency, LDH: lactate dehydrogenase, DVT: deep venous thrombosis, 
non-STEMI: non ST-Elevation Myocardial Infarction, NA: not available. Numbers in bold font indicate 
levels outside normal range. 
Patie
nt ID 
Se
x 
Diagnos
is 
Age at 
diagno
sis 
JAK2V6
17F 
(VAF%) 
CALR 
mutati
on 
CALR 
(VAF
%) 
Hemoglo
bin 
(mmol/L
) 
Platel
ets 
(x10
9
/
L) 
Leukocy
tes 
(x10
9
/L) 
LD
H 
(U/
L) 
Thromb
osis 
Follow
-up 
(mont
hs) 
1 M ET 75 0.02 Type 1 44 8.8 1076 11 321 non-STEMI 69 
2 F ET 58 0.02 Type 1 28 9.2 1273 6 289 DVT 62 
3 F 
Unclassifi
able 
85 0.01 Type 2 27 8.5 859 9.1 335  33 
4 F PMF 49 0.01 Type 1 15 9.3 229 6.9 289 DVT 43 
5 F ET 69 0.06 Type 2 35 9.4 1010 8.6 228  52 
6 F ET 54 0.09 Type 2 33 7.7 1354 7.3 219  56 
7 M PMF 67 0.1 Type 1 40 7.4 674 11.1 491  48 
8 F ET 72 0.5 Type 2 41 8.2 1584 12.7 292  55 
9 M ET 47 0.01 Type 2 43 9.2 1881 10 378  204 
10 M ET 61 0.02 Type 2 44 9.5 906 6.5 NA  154 
11 M ET 77 0.03 Type 2 36 8.0 1131 9.7 412 DVT 40 
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12 M ET 52 0.1 Type 2 41 9.7 1259 9 190  145 
13 F PMF (5q-) 74 1 Type 2 25 5.8 73 8.5 570  46 
14 M 
Unclassifi
able 
57 3 Type 2 9 9.8 617 7.8 182  43 
15 M ET 76 3 Type 1 32 8.6 715 10.2 274  49 
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